Merck announced on Nov. 7, 2020 that it is entering into a collaboration with Transcenta, a biotherapeutics company, to initiate continuous manufacturing for protein therapeutics.

Transcenta, a privately-owned, US-China-based integrated biopharmaceutical company, is in the process of marching ahead with an initial public offering (IPO) after receiving a USD 100m Series B+ funding this January, according to company Chief Executive Ofcer Dr. Xueming Qian and Executive Chairman Dr. Jonathan Zhao. The two co-founders said that the company is in crossover funding talks with potential investors, and aims to kick off the Hong Kong IPO at the end of this year.

After announcing a $100 million Series B+ funding, the biotech company’s CEO tells FinanceAsia it is now in full IPO preparation mode with Hong Kong as its preferred destination. However, a dual listing is not out of the question.

Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

“I did not want to work on an antibody similar to the dozens already in clinical trials, I wanted to find a differentiator!”